New Drug Offers Hope for Blood Cancer Patients

A novel once-daily pill, mezigdomide, combined with existing treatments, offers renewed hope for individuals battling multiple myeloma, an incurable blood cancer. Clinical trials presented at the American Society of Clinical Oncology annual meeting in Chicago revealed that patients receiving this triplet therapy lived more than twice as long without their disease progressing.

This groundbreaking research involved 479 patients diagnosed with relapsed or refractory multiple myeloma. The mezigdomide group, receiving a combination of mezigdomide, carfilzomib, and dexamethasone, experienced a median of 18 months without disease progression. In contrast, patients on a two-drug regimen of carfilzomib and dexamethasone had a median of 8.3 months.

Furthermore, the study demonstrated significant improvements in response rates. Over a quarter of patients in the mezigdomide group achieved no evidence of disease, compared to just 8.9% in the control group. Mezigdomide works by targeting specific proteins vital for cancer cell survival and stimulating the immune system to fight the cancer.

While approximately 6,200 people in the UK are diagnosed with multiple myeloma each year, options for relapsed or refractory cases are limited. Experts suggest that mezigdomide could become a new standard of care. The National Institute for Health and Care Excellence is currently assessing the drug's potential inclusion on the NHS for eligible patients in England.